Dulles, VA, November 4, 2020 – SOFIE, whose vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics, announced today the completion of a $27.4m Series C financing of the company, led by Jubilant Pharma and syndicated by three other investors. 

Patrick Phelps, SOFIE’s President and Chief Executive Officer stated, “With this investment and strategic partnership, SOFIE is excited to meet the growing need to manufacture highly specialized radiopharmaceuticals, as well as become the first theranostic production center for FAPI in the US. FAPI has received worldwide acclaim for its value as a key next-generation theranostic agent with the ability to greatly enhance the detection and treatment of disease, and we believe with Jubilant Radiopharma’s investment and support, we can accelerate the development and commercialization of this exciting family of compounds.”

Philipp Czernin, SOFIE’s Chief Revenue Officer, remarked, “By engaging a well-established industry partner such as Jubilant Radiopharma, SOFIE will leverage the combined market presence and astute organizational structure to deliver breakthrough compounds to the nuclear medicine community. With their respective distribution capabilities and the highly complementary product portfolio of SPECT and PET radiopharmaceuticals, our companies are well poised to create a single-vendor opportunity in select geographies.”

To read the full press release click here.